Does NAD+ IV Therapy Actually Work? What the Human Evidence Shows

Here is the short answer, before the detail. Oral NAD+ precursors have real randomised trial data behind them: they raise blood NAD+ reliably, they have been safe in the doses studied, and a small number of trials show modest functional effects in specific populations. Intravenous NAD+ has far less. There is a sound mechanism, one small published human pharmacokinetic study, decades of clinical use and a large volume of consistent patient report. That is a reasonable basis for trying it. It is not a basis for promising anything.

The Background, in One Paragraph

NAD+ is a coenzyme your cells use for energy production, DNA repair and sirtuin signalling, and the available pool declines with age. If you want that story properly, we cover it in why NAD+ declines with age. The rest of this article assumes it and moves on to the part people rarely get told: what has actually been tested in humans.

What Has Been Tested in People

Oral precursors: the strongest data

The best human evidence in this whole field is for NMN and NR taken by mouth.

In a 10-week randomised, placebo-controlled, double-blind trial published in Science, Yoshino and colleagues gave NMN to postmenopausal women with prediabetes who were overweight or obese. Insulin-stimulated glucose disposal measured by hyperinsulinaemic-euglycaemic clamp, and skeletal muscle insulin signalling, both increased with NMN and did not change with placebo (DOI: 10.1126/science.abe9985, PMID 33888596). Worth noting what that trial does and does not say: it is a real randomised result in a specific population, and it measured insulin sensitivity, not energy, mood or aging.

Igarashi and colleagues ran a placebo-controlled, randomised, double-blind, parallel-group trial giving 250 mg of NMN daily to healthy older men for 6 or 12 weeks, published in npj Aging. Supplementation was well tolerated, caused no significant harm, and significantly raised blood NAD+ and NAD+ metabolites. There were nominally significant improvements in gait speed and left grip performance, which the authors themselves said need validating in larger studies, and no significant effect on body composition (DOI: 10.1038/s41514-022-00084-z, PMID 35927255).

Yaku and Nakagawa's review of the human trial landscape in Antioxidants & Redox Signaling reached the summary I would give a patient: oral NR and NMN are safe and significantly raise NAD+ in humans, but efficacy on outcomes has been lower than the preclinical results predicted (DOI: 10.1089/ars.2023.0354, PMID 37335049).

Intravenous NAD+: much thinner

This is the part that usually gets skipped.

The most directly relevant published human study of IV NAD+ is a small pilot by Grant and colleagues in Frontiers in Aging Neuroscience, which tracked plasma and urine NAD+ and its metabolites during and after a 6-hour intravenous infusion. The findings were genuinely surprising: at that infusion rate, no change in plasma NAD+ or its metabolites was detectable for the first two hours, suggesting NAD+ was being rapidly and completely removed from plasma, with increased urinary excretion of NAD+ and methylnicotinamide by 6 hours (DOI: 10.3389/fnagi.2019.00257, PMID 31572171). It was a pilot study in a small cohort, and it measured metabolite handling, not symptoms.

I include it because it is the honest centre of this topic. It tells us infused NAD+ is taken up and processed quickly. It does not tell us that an infusion makes anyone feel better, and there is no large randomised trial of IV NAD+ for fatigue, cognition or aging to point to.

The brain claims

Claims that NAD+ protects the aging brain rest largely on mechanism and disease-model work, well summarised in the Cell Metabolism review by Lautrup, Sinclair, Mattson and Fang (DOI: 10.1016/j.cmet.2019.09.001, PMID 31577933). That is a legitimate scientific rationale. It is not clinical proof, and no NAD+ product has been shown to prevent or treat neurodegenerative disease.

How to Read a NAD+ Claim

Four questions will get you through almost any marketing page.

1. Was it a human study? A large share of impressive NAD+ findings are in mice or in cells.
2. Was it the same route? Evidence for oral NMN does not automatically transfer to an IV, and vice versa.
3. What was the actual outcome measured? "Raised blood NAD+" is a biomarker, not a benefit. Insulin sensitivity, grip strength and gait speed are outcomes.
4. How many people, and for how long? Ten-week trials in dozens of people cannot tell you anything about aging over decades.

What Patients Consistently Report

Patient report is not trial evidence, and I will not dress it up as such. It is still worth describing accurately, because it is part of why this treatment persists.

The most common pattern people describe is a lift in mental clarity and steadier energy within one to three days, with less of a mid-afternoon crash. Over the following weeks some report better sleep, and after a short series, easier recovery from training. It is not a stimulant, so there is no coffee-like buzz. For more on what patients report from NAD+ IV therapy, see our guide to NAD+ IV therapy benefits.

What it does not do is equally consistent: it does not replace missing hormones, correct iron or thyroid problems, or cause weight loss on its own. If any of those is the real driver of how you feel, an infusion will disappoint you, and that is precisely why we work the diagnosis first.

What I Do With This in Clinic

I treat the evidence as permission to try in the right person, not as a promise. That means the basics get checked and corrected first: thyroid, iron, B12, blood sugar, hormones, sleep quality, medications, mood. When those are handled and someone still wants energy support, a short NAD+ series is a reasonable thing to trial, with an honest conversation about the state of the evidence and a clear plan to stop if it does nothing.

That is also the standard I would want applied to me as a patient.

Frequently Asked Questions

Is there a randomised controlled trial of IV NAD+ for fatigue?

Not one I can point you to. The published human IV work is small and pharmacokinetic. Anyone citing a large IV trial for energy or aging should be asked for the reference.

Is the oral evidence good enough to just take NMN or NR instead?

The oral evidence is genuinely better, which surprises people. Whether that makes it the right choice for you depends on your goals and timeline. We compare the two precursors directly in NMN vs NR, which precursor actually reaches your cells.

Does raising blood NAD+ mean my cells got more?

Not necessarily, and this is one of the field's open problems. Blood levels are what is easy to measure; tissue levels are what matter, and the relationship between the two is still being worked out.

Has IV NAD+ been shown to be safe?

The published human work and long clinical use have not raised safety signals at the doses used, and the common effects, such as chest tightness or abdominal cramping, are rate-dependent and ease when the infusion is slowed. Safety still depends on proper screening, which is why we take a full history and review labs first.

Why do so many articles sound more certain than this one?

Because certainty sells better than accuracy. The state of the science is interesting and incomplete, and you deserve to hear it that way.

What would change my mind?

An adequately powered randomised trial of IV NAD+ with a patient-relevant primary outcome, fatigue or cognition, over a meaningful follow-up. If that arrives and is negative, I will say so here.

The Next Step

If you want to talk through whether this is worth trying in your situation, the first step is the $35 consultation, where we review your history, labs and goals. You can also see the kinds of patients we work with in the five profiles I see every week, and for practical treatment detail see our main NAD+ IV therapy guide.

Arbour Longevity - 2217 Packard St #15, Ann Arbor, MI 48104 - (734) 436-3357 - Open Thursday through Monday, 10:00 to 19:00, closed Tuesday and Wednesday. Parking is free and directly outside, with no meters and no structure. Suite 15 is down a flight of stairs, so please call ahead if stairs are difficult for you.

References

1. Grant R, Berg J, Mestayer R, et al. A pilot study investigating changes in the human plasma and urine NAD+ metabolome during a 6 hour intravenous infusion of NAD+. Front Aging Neurosci. 2019;11:257. PMID 31572171. DOI: 10.3389/fnagi.2019.00257
2. Yoshino M, Yoshino J, Kayser BD, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372(6547):1224-1229. PMID 33888596. DOI: 10.1126/science.abe9985
3. Igarashi M, Nakagawa-Nagahama Y, Miura M, et al. Chronic nicotinamide mononucleotide supplementation elevates blood NAD+ levels and alters muscle function in healthy older men. npj Aging. 2022;8(1):5. PMID 35927255. DOI: 10.1038/s41514-022-00084-z
4. Yaku K, Nakagawa T. NAD+ precursors in human health and disease: current status and future prospects. Antioxid Redox Signal. 2023;39(16-18):1133-1149. PMID 37335049. DOI: 10.1089/ars.2023.0354
5. Lautrup S, Sinclair DA, Mattson MP, Fang EF. NAD+ in brain aging and neurodegenerative disorders. Cell Metab. 2019;30(4):630-655. PMID 31577933. DOI: 10.1016/j.cmet.2019.09.001
6. Covarrubias AJ, Perrone R, Grozio A, Verdin E. NAD+ metabolism and its roles in cellular processes during ageing. Nat Rev Mol Cell Biol. 2021;22(2):119-141. PMID 33353981. DOI: 10.1038/s41580-020-00313-x

Citations verified against PubMed. This article is educational and does not replace individualized medical advice.